Neuroblastoma Clinical Trials

105 recruiting

Frequently Asked Questions

Common questions about Neuroblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 105 trials

Recruiting
Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NeuroblastomaGanglioneuroblastoma, Nodular
National Cancer Institute (NCI)478 enrolled175 locationsNCT06172296
Recruiting

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Endocrine TumorsNeuroblastomaThyroid Neoplasms+2 more
National Cancer Institute (NCI)2,415 enrolled1 locationNCT01005654
Recruiting
Phase 2

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

PheochromocytomaNeuroblastoma
Memorial Sloan Kettering Cancer Center200 enrolled1 locationNCT00107289
Recruiting
Phase 2

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

Neuroblastoma
Memorial Sloan Kettering Cancer Center286 enrolled1 locationNCT04936529
Recruiting
Phase 1Phase 2

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

OsteosarcomaEwing SarcomaNeuroblastoma+10 more
University of Florida27 enrolled1 locationNCT06625190
Recruiting

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

SarcomaEndocrine TumorsNeuroblastoma+2 more
National Cancer Institute (NCI)6,035 enrolled5 locationsNCT01109394
Recruiting
Phase 1Phase 2

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Diffuse Large B Cell LymphomaEwing SarcomaNeuroblastoma+2 more
Merck Sharp & Dohme LLC90 enrolled66 locationsNCT06395103
Recruiting
Phase 2

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

NeuroblastomaHigh Risk NeuroblastomaMetastatic Neuroblastoma
Memorial Sloan Kettering Cancer Center94 enrolled7 locationsNCT06057948
Recruiting
Phase 1Phase 2

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

OsteosarcomaEwing SarcomaNeuroblastoma+3 more
Milton S. Hershey Medical Center289 enrolled6 locationsNCT06465199
Recruiting
Phase 2

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Neuroblastoma
Giselle Sholler98 enrolled11 locationsNCT06540963
Recruiting
Phase 1Phase 2

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

OsteosarcomaEwing SarcomaNeuroblastoma+2 more
Milton S. Hershey Medical Center104 enrolled20 locationsNCT06541262
Recruiting
Early Phase 1

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

NeuroblastomaPineoblastomaAtypical Teratoid/Rhabdoid Tumor+11 more
C17 Council15 enrolled12 locationsNCT06942039
Recruiting
Phase 3

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

NeuroblastomaGanglioneuroblastoma, NodularGanglioneuroblastoma
Children's Oncology Group750 enrolled162 locationsNCT03126916
Recruiting
Phase 1

A Study of Avutometinib for People With Solid Tumor Cancers

Solid TumorSolid Tumor, AdultNeuroblastoma+12 more
Memorial Sloan Kettering Cancer Center23 enrolled2 locationsNCT06104488
Recruiting
Phase 1Phase 2

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 2

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Neuroblastoma
Giselle Sholler500 enrolled27 locationsNCT02559778
Recruiting
Phase 2

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Neuroblastoma
Y-mAbs Therapeutics122 enrolled26 locationsNCT03363373
Recruiting
Phase 1

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

Neuroblastoma
National Cancer Institute (NCI)34 enrolled1 locationNCT06995872
Recruiting
Phase 2

A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma

Neuroblastoma Recurrent
St. Jude Children's Research Hospital54 enrolled1 locationNCT07085338
Recruiting
Not Applicable

Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

NeuroblastomaHigh Risk Neuroblastoma
Dana-Farber Cancer Institute84 enrolled6 locationsNCT06831552